A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: HPV testing is replacing cytology for cervical cancer screening because of greater sensitivity and superior reassurance following negative tests for the dozen HPV genotypes that cause cervical cancer. Management of women testing positive is unresolved. The need for identification of individual HPV genotypes for clinical use is debated. Also, it is unclear how long to observe persistent infections when precancer is not initially found. METHODS: In the longitudinal NCI-Kaiser Permanente Northern California Persistence and Progression (PaP) Study, we observed the clinical outcomes (clearance, progression to CIN3+, or persistence without progression) of 11,573 HPV-positive women aged 30-65 yielding 14,158 type-specific infections. FINDINGS: Risks of CIN3+ progression differed substantially by type, with HPV16 conveying uniquely elevated risk (26% of infections with seven-year CIN3+ risk of 22%). The other carcinogenic HPV types fell into 3 distinct seven-year CIN3+ risk groups: HPV18, 45 (13% of infections, risks >5%, with known elevated cancer risk); HPV31, 33, 35, 52, 58 (39%, risks >5%); and HPV39, 51, 56, 59, 68 (23%, risks <5%). In the absence of progression, HPV clearance rates were similar by type, with 80% of infections no longer detected within three years; persistence to seven years without progression was uncommon. The predictive value of abnormal cytology was most evident for prevalent CIN3+, but less evident in follow-up. A woman's age did not modify risk; rather it was the duration of persistence that was important. INTERPRETATION: HPV type and persistence are the major predictors of progression to CIN3+; at a minimum, distinguishing HPV16 is clinically important. Dividing the other HPV types into three risk-groups is worth considering.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carcinogenic human papillomavirus infection
Schiffman, M., Doorbar, J., Wentzensen, N., de Sanjosé, S., Fakhry, C., Monk, B. J., Stanley, M. A., & Franceschi, S. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.86 · Cited by 999
Self-citationDillner, J., Rebolj, M., Birembaut, P., Petry, K.-U., Szarewski, A., Munk, C., de Sanjose, S., Naucler, P., Lloveras, B., Kjaer, S., et al. (2008) · BMJ · doi:10.1136/bmj.a1754 · Cited by 629
Demarco, M., Carter-Pokras, O., Hyun, N., Castle, P. E., He, X., Dallal, C. M., Chen, J., Gage, J. C., Befano, B., Fetterman, B., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01910-17 · Cited by 29 · cited 1×
“The natural history of type-specific infections was analyzed based on positivity of any one (or more) of the assays used, because all of the major HPV DNA tests had roughly equivalent sensitivity for the types they distinguished [16].”
MethodSelf-citation
Cited by
Fontham, E. T. H., Wolf, A. M. D., Church, T. R., Etzioni, R., Flowers, C. R., Herzig, A., Guerra, C. E., Oeffinger, K. C., Shih, Y. T., Walter, L. C., et al. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21628 · Cited by 968
Cervical Cancer Screening: A Review
Perkins, R. B., Wentzensen, N., Guido, R. S., & Schiffman, M. (2023) · JAMA · doi:10.1001/jama.2023.13174 · Cited by 492
Self-citationBenevolo, M., Ronco, G., Mancuso, P., Carozzi, F., De Marco, L., Allia, E., Bisanzi, S., Rizzolo, R., Gustinucci, D., Del Mistro, A., et al. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2024.105149 · Cited by 19
Self-citationBukowski, A., Hoyo, C., Hudgens, M. G., Brewster, W. R., Valea, F., Bentley, R. C., Vidal, A. C., Maguire, R. L., Schmitt, J. W., Murphy, S. K., et al. (2022) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-22-0054 · Cited by 9
Yuan, M., Zhao, X., Hu, S., Zhao, S., Pan, Q., Zhang, X., Duan, X., & Zhao, F. (2026) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2025.0415 · Cited by 1
Metadata
- Authors
- Demarco, M., Hyun, N., Carter-Pokras, O., Raine-Bennett, T. R., Cheung, L., Chen, X., Hammer, A., Campos, N., Kinney, W., Gage, J. C., Befano, B., Perkins, R. B., He, X., Dallal, C., Chen, J., Poitras, N., Mayrand, M.-H., Coutlee, F., Burk, R. D., Lorey, T., Castle, P. E., Wentzensen, N., & Schiffman, M.
- Venue
- EClinicalMedicine
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 22
- Pages
- 100293
- ISSN
- 2589-5370 (ISSN-L)
- OpenAlex
- W3020439257
- Cited by
- 221
- References
- 3
- FWCI
- 16.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.